-
M.
Qiao,
Tao
Jiang,
Xinyu
Liu,
S.
Mao,
F.
Zhou,
Xue-Fei
Li,
Chao
Zhao,
Xiaoxia
Chen,
C.
Su,
S.
Ren,
Caicun
Zhou
(2021)
Immune checkpoint inhibitors in EGFR-mutated non-small cell lung cancer: Dusk or Dawn?
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
-
E.
Haura,
B.
Cho,
J.
Lee,
Ji-Youn
Han,
K.
Lee,
R.
Sanborn,
R.
Govindan,
E.
Cho,
Sang-We
Kim,
K.
Reckamp,
J.
Sabari,
M.
Thayu,
K.
Bae,
R.
Knoblauch,
J.
Curtin,
N.
Haddish-Berhane,
L.
Sherman,
M.
Lorenzi,
Keunchil
Park,
J.
Bauml
(2019)
JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology
-
(
ChoBC
ChengY
ZhouC
, et al. Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study. Ann Oncol. 2018;29:483.)
ChoBC
ChengY
ZhouC
, et al. Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study. Ann Oncol. 2018;29:483.
ChoBC
ChengY
ZhouC
, et al. Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study. Ann Oncol. 2018;29:483.,
ChoBC
ChengY
ZhouC
, et al. Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study. Ann Oncol. 2018;29:483.
-
M
Qiao,
T
Jiang,
X
Liu
(2021)
Immune checkpoint inhibitors in EGFR-mutated NSCLC: dusk or dawn?
J Thorac Oncol, 16
-
(
BylickiO
GuisierF
MonnetI
, et al. Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pre-treated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adeno-carcinoma. Medicine (Baltimore). 2020;99:e18726.)
BylickiO
GuisierF
MonnetI
, et al. Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pre-treated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adeno-carcinoma. Medicine (Baltimore). 2020;99:e18726.
BylickiO
GuisierF
MonnetI
, et al. Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pre-treated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adeno-carcinoma. Medicine (Baltimore). 2020;99:e18726.,
BylickiO
GuisierF
MonnetI
, et al. Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pre-treated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adeno-carcinoma. Medicine (Baltimore). 2020;99:e18726.
-
O
Bylicki,
F
Guisier,
I
Monnet
(2020)
Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pre-treated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adeno-carcinoma
Medicine (Baltimore), 99
-
(
FuchsV
RoismanL
KianW
, et al. The impact of osimertinib’ line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance. Lung Cancer. 2021;153:126-133.33486418)
FuchsV
RoismanL
KianW
, et al. The impact of osimertinib’ line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance. Lung Cancer. 2021;153:126-133.33486418
FuchsV
RoismanL
KianW
, et al. The impact of osimertinib’ line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance. Lung Cancer. 2021;153:126-133.33486418,
FuchsV
RoismanL
KianW
, et al. The impact of osimertinib’ line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance. Lung Cancer. 2021;153:126-133.33486418
-
(
SoriaJC
OheY
VansteenkisteJ
ReungwetwattanaT
, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113-125.29151359)
SoriaJC
OheY
VansteenkisteJ
ReungwetwattanaT
, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113-125.29151359
SoriaJC
OheY
VansteenkisteJ
ReungwetwattanaT
, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113-125.29151359,
SoriaJC
OheY
VansteenkisteJ
ReungwetwattanaT
, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113-125.29151359
-
(
RangachariD
ToC
ShpilskyJE
, et al. EGFR-mutated lung cancers resistant to osimertinib through EGFR C797S respond to first-generation reversible EGFR inhibitors but eventually acquire EGFR T790M/C797S in preclinical models and clinical samples. J Thorac Oncol. 2019;14:1995-2002.31377341)
RangachariD
ToC
ShpilskyJE
, et al. EGFR-mutated lung cancers resistant to osimertinib through EGFR C797S respond to first-generation reversible EGFR inhibitors but eventually acquire EGFR T790M/C797S in preclinical models and clinical samples. J Thorac Oncol. 2019;14:1995-2002.31377341
RangachariD
ToC
ShpilskyJE
, et al. EGFR-mutated lung cancers resistant to osimertinib through EGFR C797S respond to first-generation reversible EGFR inhibitors but eventually acquire EGFR T790M/C797S in preclinical models and clinical samples. J Thorac Oncol. 2019;14:1995-2002.31377341,
RangachariD
ToC
ShpilskyJE
, et al. EGFR-mutated lung cancers resistant to osimertinib through EGFR C797S respond to first-generation reversible EGFR inhibitors but eventually acquire EGFR T790M/C797S in preclinical models and clinical samples. J Thorac Oncol. 2019;14:1995-2002.31377341
-
(
RamalingamSSCY
ZhouC
OheY
, et al. LBA50 Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study. Ann Oncol. 2018;29:740.)
RamalingamSSCY
ZhouC
OheY
, et al. LBA50 Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study. Ann Oncol. 2018;29:740.
RamalingamSSCY
ZhouC
OheY
, et al. LBA50 Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study. Ann Oncol. 2018;29:740.,
RamalingamSSCY
ZhouC
OheY
, et al. LBA50 Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study. Ann Oncol. 2018;29:740.
-
(
RoperN
BrownAL
WeiJS
, et al. Clonal evolution and heterogeneity of osimertinib acquired resistance mechanisms in EGFR mutant lung cancer. Cell Rep Med. 2020;1:100007.32483558)
RoperN
BrownAL
WeiJS
, et al. Clonal evolution and heterogeneity of osimertinib acquired resistance mechanisms in EGFR mutant lung cancer. Cell Rep Med. 2020;1:100007.32483558
RoperN
BrownAL
WeiJS
, et al. Clonal evolution and heterogeneity of osimertinib acquired resistance mechanisms in EGFR mutant lung cancer. Cell Rep Med. 2020;1:100007.32483558,
RoperN
BrownAL
WeiJS
, et al. Clonal evolution and heterogeneity of osimertinib acquired resistance mechanisms in EGFR mutant lung cancer. Cell Rep Med. 2020;1:100007.32483558
-
N.
Roper,
Anna
Brown,
Jun
Wei,
S.
Pack,
C.
Trindade,
Chul
Kim,
Olivia
Restifo,
Shaojian
Gao,
Sivasish
Sindiri,
F.
Mehrabadi,
R.
Meskini,
Z.
Ohler,
T.
Maity,
Abhilash
Venugopalan,
C.
Cultraro,
E.
Akoth,
Emerson
Padiernos,
Haobin
Chen,
A.
Kesarwala,
D.
Smart,
N.
Nilubol,
A.
Rajan,
Z.
Piotrowska,
L.
Xi,
M.
Raffeld,
A.
Panchenko,
Cenk
Sahinalp,
S.
Hewitt,
Chuong
Hoang,
Javed
Khan,
U.
Guha
(2020)
Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer
Cell Reports Medicine, 1
-
P.
Ballard,
J.
Yates,
Zhenfan
Yang,
Dong-Wan
Kim,
J.
Yang,
M.
Cantarini,
K.
Pickup,
Angela
Jordan,
Mike
Hickey,
Matthew
Grist,
Matthew
Box,
P.
Johnström,
K.
Varnäs,
J.
Malmquist,
K.
Thress,
P.
Jänne,
D.
Cross
(2016)
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
Clinical Cancer Research, 22
-
D.
Cross,
S.
Ashton,
S.
Ghiorghiu,
C.
Eberlein,
A.
Caroline,
Nebhan,
P.
Spitzler,
J.
Orme,
M.
Finlay,
A.
Richard,
Ward,
M.
Mellor,
G.
Hughes,
Amar
Rahi,
V.
Jacobs,
M.
red,
Brewer,
E.
Ichihara,
Jing
Sun,
Hailing
Jin,
P.
Ballard,
Katherine
Al-Kadhimi,
R.
Rowlinson,
T.
Klinowska,
Graham
Richmond,
M.
Cantarini,
Dong-Wan
Kim,
M.
Ranson,
W.
Pao
(2014)
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
Cancer discovery, 4 9
-
Ying
Cheng,
Yong
He,
Wei
Li,
He-long
Zhang,
Qing
Zhou,
Buhai
Wang,
Chunling
Liu,
A.
Walding,
M.
Saggese,
Xiangning
Huang,
M.
Fan,
Jia
Wang,
S.
Ramalingam
(2021)
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
Targeted Oncology, 16
-
Yi-long
Wu,
Ying
Cheng,
Xiang-dong
Zhou,
K.
Lee,
K.
Nakagawa,
S.
Niho,
F.
Tsuji,
R.
Linke,
R.
Rosell,
J.
Corral,
M.
Migliorino,
A.
Płużański,
E.
Sbar,
Tao
Wang,
Jane
White,
S.
Nadanaciva,
R.
Sandin,
T.
Mok
(2017)
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
The Lancet. Oncology, 18 11
-
(
WuYL
ChengY
ZhouJ
, et al. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. Lancet Respir Med. 2020;8:1132-1143.32479794)
WuYL
ChengY
ZhouJ
, et al. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. Lancet Respir Med. 2020;8:1132-1143.32479794
WuYL
ChengY
ZhouJ
, et al. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. Lancet Respir Med. 2020;8:1132-1143.32479794,
WuYL
ChengY
ZhouJ
, et al. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. Lancet Respir Med. 2020;8:1132-1143.32479794
-
(
PiotrowskaZ
IsozakiH
LennerzJK
, et al. Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion. Cancer Discov. 2018;8:1529-1539.30257958)
PiotrowskaZ
IsozakiH
LennerzJK
, et al. Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion. Cancer Discov. 2018;8:1529-1539.30257958
PiotrowskaZ
IsozakiH
LennerzJK
, et al. Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion. Cancer Discov. 2018;8:1529-1539.30257958,
PiotrowskaZ
IsozakiH
LennerzJK
, et al. Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion. Cancer Discov. 2018;8:1529-1539.30257958
-
(
LisbergA
CummingsA
GoldmanJW
, et al. A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naive patients with advanced NSCLC. J Thorac Oncol. 2018;13:1138-1145.29874546)
LisbergA
CummingsA
GoldmanJW
, et al. A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naive patients with advanced NSCLC. J Thorac Oncol. 2018;13:1138-1145.29874546
LisbergA
CummingsA
GoldmanJW
, et al. A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naive patients with advanced NSCLC. J Thorac Oncol. 2018;13:1138-1145.29874546,
LisbergA
CummingsA
GoldmanJW
, et al. A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naive patients with advanced NSCLC. J Thorac Oncol. 2018;13:1138-1145.29874546
-
(
OxnardGR
ArcilaME
SimaCS
, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res. 2011;17:1616-1622.21135146)
OxnardGR
ArcilaME
SimaCS
, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res. 2011;17:1616-1622.21135146
OxnardGR
ArcilaME
SimaCS
, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res. 2011;17:1616-1622.21135146,
OxnardGR
ArcilaME
SimaCS
, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res. 2011;17:1616-1622.21135146
-
Z.
Piotrowska,
H.
Isozaki,
Jochen
Lennerz,
J.
Gainor,
Inga
Lennes,
V.
Zhu,
N.
Marcoux,
M.
Banwait,
S.
Digumarthy,
Wenjia
Su,
S.
Yoda,
Amanda
Riley,
Varuna
Nangia,
Jessica
Lin,
R.
Nagy,
R.
Lanman,
D.
Dias-Santagata,
M.
Mino‐Kenudson,
A.
Iafrate,
R.
Heist,
A.
Shaw,
Erica
Evans,
C.
Clifford,
Sai-Hong
Ou,
B.
Wolf,
A.
Hata,
L.
Sequist
(2018)
Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.
Cancer discovery, 8 12
-
L.
Sequist,
B.
Waltman,
D.
Dias-Santagata,
S.
Digumarthy,
Alexa
Turke,
P.
Fidias,
K.
Bergethon,
A.
Shaw,
S.
Gettinger,
A.
Cosper,
S.
Akhavanfard,
R.
Heist,
J.
Temel,
J.
Christensen,
J.
Wain,
T.
Lynch,
Kathy
Vernovsky,
E.
Mark,
M.
Lanuti,
A.
Iafrate,
M.
Mino‐Kenudson,
J.
Engelman
(2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Science Translational Medicine, 3
-
C.
Lazzari,
V.
Gregorc,
N.
Karachaliou,
R.
Rosell,
M.
Santarpia
(2020)
Mechanisms of resistance to osimertinib
Journal of Thoracic Disease, 12
-
(
YuHA
ArcilaME
RekhtmanN
, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240-2247.23470965)
YuHA
ArcilaME
RekhtmanN
, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240-2247.23470965
YuHA
ArcilaME
RekhtmanN
, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240-2247.23470965,
YuHA
ArcilaME
RekhtmanN
, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240-2247.23470965
-
Yi-long
Wu,
M.
Ahn,
M.
Garassino,
Ji-Youn
Han,
N.
Katakami,
H.
Kim,
R.
Hodge,
P.
Kaur,
Andrew
Brown,
D.
Ghiorghiu,
V.
Papadimitrakopoulou,
T.
Mok
(2018)
CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36 26
-
(
CrossDA
AshtonSE
GhiorghiuS
, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4:1046-1061.24893891)
CrossDA
AshtonSE
GhiorghiuS
, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4:1046-1061.24893891
CrossDA
AshtonSE
GhiorghiuS
, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4:1046-1061.24893891,
CrossDA
AshtonSE
GhiorghiuS
, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4:1046-1061.24893891
-
L.
Sequist,
Ji-Youn
Han,
M.
Ahn,
B.
Cho,
H.
Yu,
Sang-We
Kim,
J.
Yang,
J.
Lee,
W.
Su,
D.
Kowalski,
S.
Orlov,
M.
Cantarini,
R.
Verheijen,
A.
Mellemgaard,
L.
Ottesen,
P.
Frewer,
X.
Ou,
G.
Oxnard
(2020)
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
The Lancet. Oncology
-
S.
Ramalingam,
J.
Vansteenkiste,
D.
Planchard,
B.
Cho,
J.
Gray,
Y.
Ohe,
Caicun
Zhou,
T.
Reungwetwattana,
Ying
Cheng,
B.
Chewaskulyong,
R.
Shah,
M.
Cobo,
K.
Lee,
P.
Cheema,
M.
Tiseo,
T.
John,
Meng-Chih
Lin,
F.
Imamura,
T.
Kurata,
A.
Todd,
R.
Hodge,
M.
Saggese,
Y.
Rukazenkov,
J.
Soria
(2019)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
The New England journal of medicine
-
(
MehlmanC
CadranelJ
Rousseau-BussacG
, et al. Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: a multicentric retrospective French study. Lung Cancer. 2019;137:149-156.31600593)
MehlmanC
CadranelJ
Rousseau-BussacG
, et al. Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: a multicentric retrospective French study. Lung Cancer. 2019;137:149-156.31600593
MehlmanC
CadranelJ
Rousseau-BussacG
, et al. Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: a multicentric retrospective French study. Lung Cancer. 2019;137:149-156.31600593,
MehlmanC
CadranelJ
Rousseau-BussacG
, et al. Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: a multicentric retrospective French study. Lung Cancer. 2019;137:149-156.31600593
-
Zhe
Yang,
N.
Yang,
Q.
Ou,
Y.
Xiang,
T.
Jiang,
Xue
Wu,
H.
Bao,
X.
Tong,
Xiaonan
Wang,
Y.
Shao,
Yunpeng
Liu,
Yan
Wang,
Caicun
Zhou
(2018)
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
Clinical Cancer Research, 24
-
(
HauraEB
ChoBC
LeeJS
, et al. JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2019;37:9009-9009.)
HauraEB
ChoBC
LeeJS
, et al. JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2019;37:9009-9009.
HauraEB
ChoBC
LeeJS
, et al. JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2019;37:9009-9009.,
HauraEB
ChoBC
LeeJS
, et al. JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2019;37:9009-9009.
-
(
LeeCK
ManJ
LordS
, et al. Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis. JAMA Oncol. 2018;4:210-216.29270615)
LeeCK
ManJ
LordS
, et al. Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis. JAMA Oncol. 2018;4:210-216.29270615
LeeCK
ManJ
LordS
, et al. Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis. JAMA Oncol. 2018;4:210-216.29270615,
LeeCK
ManJ
LordS
, et al. Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis. JAMA Oncol. 2018;4:210-216.29270615
-
Suresh
Ramalingam,
Y.
Cheng,
C.
Zhou,
Yuichiro
Ohe,
Fumio
Imamura,
B.
Cho,
M.-C.
Lin,
M.
Majem,
R.
Shah,
Y.
Rukazenkov,
A.
Todd,
A.
Markovets,
J.
Barrett,
J.
Chmielecki,
J.
Gray
(2018)
Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study.
Annals of oncology : official journal of the European Society for Medical Oncology, 29 Suppl 8
-
G.
Oxnard,
Yuebi
Hu,
K.
Mileham,
H.
Husain,
D.
Costa,
P.
Tracy,
N.
Feeney,
L.
Sholl,
S.
Dahlberg,
A.
Redig,
D.
Kwiatkowski,
M.
Rabin,
C.
Paweletz,
K.
Thress,
P.
Jänne
(2018)
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
JAMA Oncology, 4
-
(
RamalingamSS
VansteenkisteJ
PlanchardD
, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41-50.31751012)
RamalingamSS
VansteenkisteJ
PlanchardD
, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41-50.31751012
RamalingamSS
VansteenkisteJ
PlanchardD
, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41-50.31751012,
RamalingamSS
VansteenkisteJ
PlanchardD
, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41-50.31751012
-
A.
Schoenfeld,
H.
Yu
(2020)
The Evolving Landscape of Resistance to Osimertinib.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 15 1
-
J.
Soria,
Y.
Ohe,
J.
Vansteenkiste,
T.
Reungwetwattana,
B.
Chewaskulyong,
K.
Lee,
A.
Dechaphunkul,
F.
Imamura,
N.
Nogami,
T.
Kurata,
I.
Okamoto,
Caicun
Zhou,
B.
Cho,
Ying
Cheng,
E.
Cho,
P.
Voon,
D.
Planchard,
Wu‐Chou
Su,
J.
Gray,
S.
Lee,
R.
Hodge,
M.
Marotti,
Y.
Rukazenkov,
S.
Ramalingam
(2018)
Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer
The New England Journal of Medicine, 378
-
(
QiaoM
JiangT
LiuX
, et al. Immune checkpoint inhibitors in EGFR-mutated NSCLC: dusk or dawn?
J Thorac Oncol. 2021;16:1267-1288.33915248)
QiaoM
JiangT
LiuX
, et al. Immune checkpoint inhibitors in EGFR-mutated NSCLC: dusk or dawn?
J Thorac Oncol. 2021;16:1267-1288.33915248
QiaoM
JiangT
LiuX
, et al. Immune checkpoint inhibitors in EGFR-mutated NSCLC: dusk or dawn?
J Thorac Oncol. 2021;16:1267-1288.33915248,
QiaoM
JiangT
LiuX
, et al. Immune checkpoint inhibitors in EGFR-mutated NSCLC: dusk or dawn?
J Thorac Oncol. 2021;16:1267-1288.33915248
-
(
SaitoH
FukuharaT
FuruyaN
, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive ad-vanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019;20:625-635.30975627)
SaitoH
FukuharaT
FuruyaN
, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive ad-vanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019;20:625-635.30975627
SaitoH
FukuharaT
FuruyaN
, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive ad-vanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019;20:625-635.30975627,
SaitoH
FukuharaT
FuruyaN
, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive ad-vanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019;20:625-635.30975627
-
Yi-long
Wu,
Ying
Cheng,
Jianying
Zhou,
Shun
Lu,
Yiping
Zhang,
Jun
Zhao,
Dong-Wan
Kim,
R.
Soo,
Sang-We
Kim,
H.
Pan,
Yuh-Min
Chen,
C.
Chian,
Xiaoqing
Liu,
D.
Tan,
R.
Bruns,
J.
Straub,
A.
Johne,
J.
Scheele,
Keunchil
Park,
J.
Yang
(2020)
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
The Lancet. Respiratory medicine
-
A.
Lisberg,
A.
Cummings,
J.
Goldman,
K.
Bornazyan,
N.
Reese,
T.
Wang,
P.
Coluzzi,
B.
Ledezma,
M.
Mendenhall,
Jaime
Hunt,
Brian
Wolf,
Benjamin
Jones,
John
Madrigal,
John
Horton,
M.
Spiegel,
J.
Carroll,
Jaklin
Gukasyan,
T.
Williams,
Lauren
Sauer,
C.
Wells,
Ariana
Hardy,
P.
Linares,
C.
Lim,
L.
Ma,
Carlos
Adame,
E.
Garon
(2017)
A Phase II Study of Pembrolizumab in EGFR‐Mutant, PD‐L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC
Journal of Thoracic Oncology, 13
-
(
ChengY
HeY
LiW
, et al. Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, a randomized study. Target Oncol. 2021;16:165-176.33544337)
ChengY
HeY
LiW
, et al. Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, a randomized study. Target Oncol. 2021;16:165-176.33544337
ChengY
HeY
LiW
, et al. Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, a randomized study. Target Oncol. 2021;16:165-176.33544337,
ChengY
HeY
LiW
, et al. Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, a randomized study. Target Oncol. 2021;16:165-176.33544337
-
(
MasudaK
HorinouchiH
TanakaM
, et al. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression. J Cancer Res Clin Oncol. 2021;147:245-251.32705363)
MasudaK
HorinouchiH
TanakaM
, et al. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression. J Cancer Res Clin Oncol. 2021;147:245-251.32705363
MasudaK
HorinouchiH
TanakaM
, et al. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression. J Cancer Res Clin Oncol. 2021;147:245-251.32705363,
MasudaK
HorinouchiH
TanakaM
, et al. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression. J Cancer Res Clin Oncol. 2021;147:245-251.32705363
-
C.
Mehlman,
J.
Cadranel,
G.
Rousseau-Bussac,
R.
Lacave,
A.
Pujals,
N.
Girard,
C.
Callens,
V.
Gounant,
N.
Theou-Anton,
S.
Friard,
J.
Trédaniel,
H.
Blons,
C.
Dujon,
B.
Duchemann,
P.
Schischmanoff,
T.
Chinet,
E.
Leprieur
(2019)
Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study.
Lung cancer, 137
-
(
WangY
TianP
XiaL
, et al. The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy. Lung Cancer. 2020;146:165-173.32540560)
WangY
TianP
XiaL
, et al. The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy. Lung Cancer. 2020;146:165-173.32540560
WangY
TianP
XiaL
, et al. The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy. Lung Cancer. 2020;146:165-173.32540560,
WangY
TianP
XiaL
, et al. The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy. Lung Cancer. 2020;146:165-173.32540560
-
H.
Yu,
M.
Arcila,
N.
Rekhtman,
C.
Sima,
M.
Zakowski,
W.
Pao,
M.
Kris,
V.
Miller,
M.
Ladanyi,
Gregory
Riely
(2013)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Clinical Cancer Research, 19
-
(
SequistLV
HanJY
AhnMJ
, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020;21:373-386.32027846)
SequistLV
HanJY
AhnMJ
, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020;21:373-386.32027846
SequistLV
HanJY
AhnMJ
, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020;21:373-386.32027846,
SequistLV
HanJY
AhnMJ
, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020;21:373-386.32027846
-
M.
Niederst,
Haichuan
Hu,
Hillary
Mulvey,
Elizabeth
Lockerman,
Angel
Garcia,
Z.
Piotrowska,
L.
Sequist,
J.
Engelman
(2015)
The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
Clinical Cancer Research, 21
-
(
LazzariC
GregorcV
KarachaliouN
, et al. Mechanisms of resistance to osimertinib. J Thorac Dis. 2020;12:2851-2858.32642198)
LazzariC
GregorcV
KarachaliouN
, et al. Mechanisms of resistance to osimertinib. J Thorac Dis. 2020;12:2851-2858.32642198
LazzariC
GregorcV
KarachaliouN
, et al. Mechanisms of resistance to osimertinib. J Thorac Dis. 2020;12:2851-2858.32642198,
LazzariC
GregorcV
KarachaliouN
, et al. Mechanisms of resistance to osimertinib. J Thorac Dis. 2020;12:2851-2858.32642198
-
(
SchoenfeldAJ
YuHA
. The evolving landscape of resistance to osimertinib. J Thorac Oncol. 2020;15:18-21.31864549)
SchoenfeldAJ
YuHA
. The evolving landscape of resistance to osimertinib. J Thorac Oncol. 2020;15:18-21.31864549
SchoenfeldAJ
YuHA
. The evolving landscape of resistance to osimertinib. J Thorac Oncol. 2020;15:18-21.31864549,
SchoenfeldAJ
YuHA
. The evolving landscape of resistance to osimertinib. J Thorac Oncol. 2020;15:18-21.31864549
-
Yubo
Wang,
P.
Tian,
L.
Xia,
Li
Li,
R.
Han,
Mengxiao
Zhu,
A.
Lizaso,
T.
Qin,
Min
Li,
Bing
Yu,
X.
Mao,
H.
Han‐Zhang,
Yong
He
(2020)
The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy.
Lung cancer, 146
-
(
YangZ
YangN
OuQ
, et al. Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhib-itor osimertinib in non-small cell lung cancer Patients. Clin Cancer Res. 2018;24:3097-3107.29506987)
YangZ
YangN
OuQ
, et al. Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhib-itor osimertinib in non-small cell lung cancer Patients. Clin Cancer Res. 2018;24:3097-3107.29506987
YangZ
YangN
OuQ
, et al. Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhib-itor osimertinib in non-small cell lung cancer Patients. Clin Cancer Res. 2018;24:3097-3107.29506987,
YangZ
YangN
OuQ
, et al. Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhib-itor osimertinib in non-small cell lung cancer Patients. Clin Cancer Res. 2018;24:3097-3107.29506987
-
(
NiederstMJ
HuH
MulveyHE
, et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin Cancer Res. 2015;21:3924-3933.25964297)
NiederstMJ
HuH
MulveyHE
, et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin Cancer Res. 2015;21:3924-3933.25964297
NiederstMJ
HuH
MulveyHE
, et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin Cancer Res. 2015;21:3924-3933.25964297,
NiederstMJ
HuH
MulveyHE
, et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin Cancer Res. 2015;21:3924-3933.25964297
-
(2019)
: a multicen - tric retrospective French study
-
(
BallardP
YatesJW
YangZ
, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016;22:5130-5140.27435396)
BallardP
YatesJW
YangZ
, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016;22:5130-5140.27435396
BallardP
YatesJW
YangZ
, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016;22:5130-5140.27435396,
BallardP
YatesJW
YangZ
, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016;22:5130-5140.27435396
-
S.
Schmid,
J.
Li,
N.
Leighl
(2020)
Mechanisms of osimertinib resistance and emerging treatment options.
Lung cancer, 147
-
Vered
Fuchs,
L.
Roisman,
W.
Kian,
L.
Daniel,
J.
Dudnik,
H.
Nechushtan,
I.
Goldstein,
A.
Dvir,
L.
Soussan-Gutman,
R.
Grinberg,
Roni
Gillis,
N.
Peled
(2021)
The impact of osimertinib' line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance.
Lung cancer, 153
-
G.
Oxnard,
M.
Arcila,
C.
Sima,
Gregory
Riely,
J.
Chmielecki,
M.
Kris,
W.
Pao,
M.
Ladanyi,
V.
Miller
(2010)
Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation
Clinical Cancer Research, 17
-
Meredith
Bollinger,
Amanda
Agnew,
Gerard
Mascara
(2018)
Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation
Journal of Oncology Pharmacy Practice, 24
-
K.
Masuda,
H.
Horinouchi,
Midori
Tanaka,
R.
Higashiyama,
Y.
Shinno,
J.
Sato,
Y.
Matsumoto,
Y.
Okuma,
T.
Yoshida,
Y.
Goto,
N.
Yamamoto,
Y.
Ohe
(2020)
Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression
Journal of Cancer Research and Clinical Oncology, 147
-
H.
Saito,
T.
Fukuhara,
N.
Furuya,
Kana
Watanabe,
S.
Sugawara,
S.
Iwasawa,
Y.
Tsunezuka,
O.
Yamaguchi,
M.
Okada,
K.
Yoshimori,
I.
Nakachi,
A.
Gemma,
K.
Azuma,
F.
Kurimoto,
Y.
Tsubata,
Y.
Fujita,
Hiromi
Nagashima,
G.
Asai,
Satoshi
Watanabe,
M.
Miyazaki,
K.
Hagiwara,
T.
Nukiwa,
S.
Morita,
K.
Kobayashi,
M.
Maemondo
(2019)
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
The Lancet. Oncology, 20 5
-
(
BollingerMK
AgnewAS
MascaraGP
. Osimertinib: a third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation. J Oncol Pharm Pract. 2018;24:379-388.28565936)
BollingerMK
AgnewAS
MascaraGP
. Osimertinib: a third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation. J Oncol Pharm Pract. 2018;24:379-388.28565936
BollingerMK
AgnewAS
MascaraGP
. Osimertinib: a third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation. J Oncol Pharm Pract. 2018;24:379-388.28565936,
BollingerMK
AgnewAS
MascaraGP
. Osimertinib: a third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation. J Oncol Pharm Pract. 2018;24:379-388.28565936
-
Deepa
Rangachari,
Ciric
To,
Jason
Shpilsky,
P.
VanderLaan,
Susumu
Kobayashi,
Mierzhati
Mushajiang,
C.
Lau,
C.
Paweletz,
G.
Oxnard,
P.
Jänne,
D.
Costa
(2019)
Brief Report: EGFR-mutated lung cancers resistant to osimertinib through EGFR-C797S respond to 1st generation reversible EGFR inhibitors but eventually acquire EGFR-T790M/C797S in preclinical models and clinical samples.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
-
C.
Lee,
J.
Man,
S.
Lord,
W.
Cooper,
M.
Links,
V.
Gebski,
R.
Herbst,
R.
Gralla,
T.
Mok,
J.
Yang
(2017)
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis
JAMA Oncology, 4
-
(
SchmidS
LiJJN
LeighlNB
. Mechanisms of osimertinib resistance emerging treatment options. Lung Cancer. 2020;147:123-129.32693293)
SchmidS
LiJJN
LeighlNB
. Mechanisms of osimertinib resistance emerging treatment options. Lung Cancer. 2020;147:123-129.32693293
SchmidS
LiJJN
LeighlNB
. Mechanisms of osimertinib resistance emerging treatment options. Lung Cancer. 2020;147:123-129.32693293,
SchmidS
LiJJN
LeighlNB
. Mechanisms of osimertinib resistance emerging treatment options. Lung Cancer. 2020;147:123-129.32693293